Results 141 to 150 of about 72,473 (300)
Pathogenic or Likely Pathogenic GRN Variants Are Found in 0.1% of Parkinson's Disease Patients
Movement Disorders, EarlyView.Abstract Background Parkinsonism may be observed in multiple neurodegenerative diseases, including GRN‐associated frontotemporal dementia (FTD‐GRN), complicating the differential diagnosis of Parkinson's disease (PD). Objectives To investigate the presence of GRN variants in a large group of PD patients.
Christian A. Ganoza +31 more
wiley +1 more source
Uncovering the Complexity of Synucleinopathies: An Ongoing Tale Between Proteins and Lipids
Movement Disorders, EarlyView.Abstract Neurodegenerative diseases are pathological states characterized by progressive alterations in brain homeostasis during aging. Synucleinopathies, including Parkinson's disease and dementia with Lewy bodies, are defined neuropathologically by the accumulation of inclusions known as Lewy bodies and Lewy neurites.
Manuel Flores‐León, Tiago F. Outeiro
wiley +1 more source
Movement Disorders, EarlyView.Variants in GBA1, the gene encoding the lysosomal enzyme glucocerebrosidase, cause Gaucher disease and confer an increased risk for parkinsonism. Strategies using small molecules can improve the function of glucocerebrosidase in lysosomes. A clear understanding of the mechanism‐of‐action of these compounds will facilitate development of GBA1‐modulating
Mark J. Henderson +5 more
wiley +1 more source
Diagnostic Value of Bedside Eye Movement Examination in Movement Disorders
Movement Disorders Clinical Practice, EarlyView.
Eloísa Bittencurt Thomaz de Assis +4 more
wiley +1 more source
Movement Disorders, EarlyView.Abstract Background Recent advances in proteomic profiling have enabled its use as a powerful approach in elucidating molecular mechanisms underlying Parkinson's disease, enabling the identification of disease‐associated protein alterations and candidate biomarkers for diagnosis, progression, and therapeutic response.
Victoria J. Dardov +21 more
wiley +1 more source
Movement Disorders, EarlyView.Abstract Background Parkinson's disease (PD) is characterized by predominantly neuronal α‐synuclein pathology and dopaminergic dysfunction. Cerebrospinal fluid (CSF) seeding amplification assays (SAA) detect α‐synuclein aggregates in vivo, but not all patients with PD have a positive SAA.
Michael Tran Duong +186 more
wiley +1 more source
Movement Disorders, EarlyView.Abstract Background Transsynaptic α‐synuclein propagation plays a crucial role in the progression of Lewy body disease. We previously demonstrated that an α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor antagonist, perampanel, blocks neuronal uptake of α‐synuclein preformed fibrils (PFFs) in an activity‐dependent manner.
Jun Ueda +9 more
wiley +1 more source
Targeting BPOZ-2 in Lewy body disease
Neural Regeneration Research, 2016 Avik Roy
doaj +1 more source
Movement Disorders, EarlyView.Abstract Background The cerebrospinal fluid alpha‐synuclein seed amplification assay (CSFasynSAA) detects alpha‐synuclein aggregation in over 90% of individuals with sporadic PD (sPD). However, the clinical characteristics of sPD with negative CSFasynSAA remain undefined.
Sarah M. Brooker +30 more
wiley +1 more source
Early Autonomic Burden in Prodromal Parkinson's Disease Predicts Cognitive Impairment
Movement Disorders, EarlyView.Abstract Background Autonomic dysfunction is a known contributor to cognitive impairment in Parkinson's disease (PD), but its impact during prodromal stage is unknown. Objective The aim was to determine whether early autonomic burden predicts incident cognitive impairment in prodromal PD.
A. Enrique Martinez‐Nunez +5 more
wiley +1 more source